Reta-R3
LY3437943
Reta-R3 is a multi-receptor agonist research peptide (GLP-1, GIP, glucagon) studied in the preclinical literature in a metabolic context. Offered exclusively as a research reagent — not for human consumption or medical use.
Key facts
- Class
- Multi-receptor agonist peptide
- Targets
- GLP-1 / GIP / glucagon
- Form
- Lyophilised (powder)
- Status
- Research Use Only
Study library
All results on PubMedTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Jastreboff AM, et al. · The New England journal of medicine · 2023
Retatrutide-A Game Changer in Obesity Pharmacotherapy.
Katsi V, et al. · Biomolecules · 2025
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Drucker DJ · Diabetes care · 2024
Emerging pharmacotherapies for obesity: A systematic review.
Kokkorakis M, et al. · Pharmacological reviews · 2025
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
Moiz A, et al. · Annals of internal medicine · 2025
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T, et al. · Cell metabolism · 2022
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Locatelli JC, et al. · Diabetes care · 2024
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Giblin K, et al. · Diabetes, obesity & metabolism · 2026
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J, et al. · Lancet (London, England) · 2023
Gut hormones and appetite regulation.
Hong SH, et al. · Current opinion in endocrinology, diabetes, and obesity · 2024
What is the pipeline for future medications for obesity?
Melson E, et al. · International journal of obesity (2005) · 2025
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.
Marathe SJ, et al. · npj metabolic health and disease · 2025
Results retrieved live from PubMed (NCBI). Research literature only — no medical advice.
Research peptides — Research Use Only
- Not for human consumption
- Not for the diagnosis, treatment or prevention of any disease